Dose‐Dependent Effect of Crocin on Depressive and Anxiety Symptom Scores: A GRADE‐Assessed Systematic Review and Meta‐Analysis of Randomized Controlled Trials
- 1Department of Nutrition School of Public Health Iran University of Medical Sciences Tehran Iran iums.ac.ir
- 2Student Research Committee Faculty of Nutrition and Food Technology Shahid Beheshti University of Medical Sciences Tehran Iran sbmu.ac.ir
- 3Nutritional Health Research Center School of Health and Nutrition Lorestan University of Medical Sciences Khorramabad Iran lums.ac.ir
Abstract
Background: Although several clinical trials have examined the effects of crocin on the symptoms of depression and anxiety, their findings have not yet been synthesized comprehensively. Therefore, this systematic review and meta‐analysis aimed to determine the dose‐dependent effect of crocin supplementation on depressive and anxiety symptom scores.
Methods: A comprehensive search was performed in the PubMed, Scopus, and ISI Web of Science until April 2026. The change in depressive and anxiety symptom scores for each 30 mg/d increase in crocin supplementation was estimated and then the standardized mean difference (SMD) with 95% CI was calculated. We also assessed the publication bias, sensitivity analysis and heterogeneity by standard methods. Certainty of evidences was evaluated through the GRADE Tool.
Results: Fourteen randomized controlled trials (RCTs) were included. Each 30 mg/day increasing in crocin supplementation can decreased scores of depressive symptoms by −3.37 (95% CI: −4.80, −1.94; I 2 = 97.1%, GRADE = moderate). A slight linear reduction in the depressive symptom scores was observed (p nonlinearity = 0.47, p dose–response = 0.001). Each 30 mg/day crocin can led to −2.73 reduction in anxiety symptom scores (95% CI: −4.17, −1.06; I 2 = 97%, GRADE = high). Anxiety symptom scores reduced with a slight linear slope (p nonlinearity = 0.9, p dose–response = 0.02).
Conclusion: In conclusion, crocin supplementation may improve symptom scores of both depression and anxiety in a dose–response manner. However, these results are based on clinical trials with relatively small sample sizes, almost conducted in one country. Well‐designed RCTs across diverse regions with adequate sample sizes are required to confirm these findings.
Trial Registration: Prospero Code: CRD42024591281
Related
- Effects of ginger intervention on anthropometric and body composition indices in patients with type 2 diabetes: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials.
- Structured physical activity, yoga, and music-based interventions for depressive symptoms in adolescents: a systematic review and meta-analysis of randomized controlled trials
- Adjunctive Psychobiotic Lactiplantibacillus plantarum PS128 Therapy and Escitalopram in Major Depressive Disorder: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial
- Ventilation distribution assessed by electrical impedance tomography during robot-assisted laparoscopic prostatectomy : A randomized controlled trial
- Qili Qiangxin capsule as adjunctive therapy for heart failure after acute myocardial infarction: a GRADE-assessed systematic review and meta-analysis of randomised controlled trials
BibTeX
@article{behrouzi2026dosedependent,
title = {{Dose‐Dependent Effect of Crocin on Depressive and Anxiety Symptom Scores: A GRADE‐Assessed Systematic Review and Meta‐Analysis of Randomized Controlled Trials}},
author = {Roya Behrouzi and Fatemeh Mehdipoor and Kimia Torabinasab and Hossein Shahinfar},
journal = {Depression and Anxiety},
year = {2026},
month = oct,
doi = {10.1155/da/8303882},
url = {https://doi.org/10.1155/da/8303882},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Dose‐Dependent Effect of Crocin on Depressive and Anxiety Symptom Scores: A GRADE‐Assessed Systematic Review and Meta‐Analysis of Randomized Controlled Trials
AU - Roya Behrouzi
AU - Fatemeh Mehdipoor
AU - Kimia Torabinasab
AU - Hossein Shahinfar
PY - 2026
DA - 2026/10/30
JO - Depression and Anxiety
DO - 10.1155/da/8303882
UR - https://doi.org/10.1155/da/8303882
AB - Background: Although several clinical trials have examined the effects of crocin on the symptoms of depression and anxiety, their findings have not yet been synthesized comprehensively. Therefore, this systematic review and meta‐analysis aimed to determine the dose‐dependent effect of crocin supplementation on depressive and anxiety symptom scores. Methods: A comprehensive search was performed in the PubMed, Scopus, and ISI Web of Science until April 2026. The change in depressive and anxiety symptom scores for each 30 mg/d increase in crocin supplementation was estimated and then the standardized mean difference (SMD) with 95% CI was calculated. We also assessed the publication bias, sensitivity analysis and heterogeneity by standard methods. Certainty of evidences was evaluated through the GRADE Tool. Results: Fourteen randomized controlled trials (RCTs) were included. Each 30 mg/day increasing in crocin supplementation can decreased scores of depressive symptoms by −3.37 (95% CI: −4.80, −1.94; I 2 = 97.1%, GRADE = moderate). A slight linear reduction in the depressive symptom scores was observed (p nonlinearity = 0.47, p dose–response = 0.001). Each 30 mg/day crocin can led to −2.73 reduction in anxiety symptom scores (95% CI: −4.17, −1.06; I 2 = 97%, GRADE = high). Anxiety symptom scores reduced with a slight linear slope (p nonlinearity = 0.9, p dose–response = 0.02). Conclusion: In conclusion, crocin supplementation may improve symptom scores of both depression and anxiety in a dose–response manner. However, these results are based on clinical trials with relatively small sample sizes, almost conducted in one country. Well‐designed RCTs across diverse regions with adequate sample sizes are required to confirm these findings. Trial Registration: Prospero Code: CRD42024591281
SN - 1091-4269
SN - 1520-6394
ER -